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Abstract
The number of imported Human African Trypanosomiasis (HAT) cases in non-endemic countries has increased over the last
years. The objective of this analysis is to describe the clinical presentation of HAT in Caucasian travelers. Literature was
screened (MEDLINE, Pubmed) using the terms ‘‘Human African Trypanosomiasis’’, ‘‘travelers’’ and ‘‘expatriates’’; all European
languages except Slavic ones were included. Publications without clinical description of patients were only included in the
epidemiological analysis. Forty-five reports on Caucasians with T.b. rhodesiense and 15 with T.b. gambiense infections were
included in the analysis of the clinical parameters. Both species have presented with fever (T.b. rhodesiense 97.8% and T.b.
gambiense 93.3%), headache (50% each) and a trypanosomal chancre (T.b. rhodesiense 84.4%, T.b. gambiense 46.7%). While
sleeping disorders dominate the clinical presentation of HAT in endemic regions, there have been only rare reports in
travelers: insomnia (T.b. rhodesiense 7.1%, T.b. gambiense 21.4%), diurnal somnolence (T.b. rhodesiense 4.8%, T.b. gambiense
none). Surprisingly, jaundice has been seen in 24.2% of the Caucasian T.b. rhodesiense patients, but has never been
described in HAT patients in endemic regions. These results contrast to the clinical presentation of T.b. gambiense and T.b.
rhodesiense HAT in Africans in endemic regions, where the presentation of chronic T.b. gambiense and acute T.b. rhodesiense
HAT is different. The analysis of 14 reports on T.b. gambiense HAT in Africans living in a non-endemic country shows that
neurological symptoms such as somnolence (46.2%), motor deficit (64.3%) and reflex anomalies (14.3%) as well as
psychiatric symptoms such as hallucinations (21.4%) or depression (21.4%) may dominate the clinical picture. Often, the
diagnosis has been missed initially: some patients have even been hospitalized in psychiatric clinics. In travelers T.b.
rhodesiense and gambiense present as acute illnesses and chancres are frequently seen. The diagnosis of HAT in Africans
living outside the endemic region is often missed or delayed, leading to presentation with advanced stages of the disease.
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Introduction
The increasing tourism to Africa is accompanied by an
increasing number of imported tropical diseases including rare
cases of Human African Trypanosomiasis (HAT). HAT, also
known as Sleeping Sickness, is caused by the protozoan parasites
Trypanosoma brucei gambiense (T.b. gambiense=West African form) and
Trypanosoma brucei rhodesiense (T.b. rhodesiense=East African form),
which are transmitted by the bite of the tsetse fly, Glossina spp.
The T.b. gambiense HAT is characterized by a chronic progressive
course, lasting months to years, leading to death if left untreated.
The T.b. rhodesiense HAT, however, is more acute and death occurs
within weeks or months. The disease appears in two stages: the first
being the early or haemo-lymphatic stage, and the second being the
late or meningo-encephalitic stage, characterized by the trypano-
some invasion of the central nervous system (CNS).
In endemic populations, a trypanosomal chancre (local infection at
the location of the tsetse fly bite) is only seen as an exception in T.b.
gambiense; however, it is seen in 19% of T.b. rhodesiense patients. Chronic
and intermittent fever, headache, pruritus, lymphadenopathy, and - to
a lesser extent - hepatosplenomegaly are the leading signs and
symptoms of the first stage. In the second stage sleep disturbances and
neuro-psychiatric disorders dominate the clinical presentation.
The diagnosis is based on the visualisation of the parasite in
peripheral blood, lymph node aspirate, cerebrospinal fluid (CSF), or
on polymerase chain reaction (PCR) technology, and serological
tests. As treatment differs markedly between first and second stage
HAT, the staging of the disease by examining the CSF is essential.
According to the definition of the WHO, an elevated white blood
cell count (WBC.5 cells/mm
3) or the presence of trypanosomes in
the CSF indicate a second stage disease [1].
In 1966 A.J. Duggan and M.P. Hutchinson reviewed 109 cases
found in Europeans and North Americans who were infected with
HAT between 1904 and 1963. They observed different clinical
presentations in travelers and expatriates compared to natives of
endemic regions. They reported that in Caucasians, the onset of
disease is invariably acute, irrespective of the species involved.
However, they documented their observations only partially with
precise data.
The first objective of this study is to assess the epidemiology and
the clinical presentation of HAT in travelers and expatriates from
non-endemic countries and to describe the differences between the
T.b. gambiense and T.b. rhodesiense cases. The second objective is to
describe the clinical features of HAT patients native to endemic
regions who migrated to non-endemic regions, mainly Europe and
North America.
Materials and Methods
We performed a Pubmed (MEDLINE) search of literature using
the key words ‘‘Human African Trypasomiasis’’, ‘‘travelers’’, and
‘‘expatriates’’ and reviewed the available references – including the
www.plosntds.org 1 November 2011 | Volume 5 | Issue 11 | e1358bibliographies of the retrieved references – published between
1967 and 2010 for eligible publications.
The inclusion criteria were all available publications written in
European languages except Slavic languages (Dutch, English,
French, German or Norwegian) on:
1. HAT patients from non-endemic regions who were diagnosed
and treated in non-endemic regions
2. HAT patients from endemic regions who were diagnosed and
treated in non-endemic regions
The exclusion criteria were publications in Slavic or Asian
languages. Reports with insufficient clinical description were only
included in the epidemiological analyses.
Additionally, unpublished HAT cases reported on ProMED-
mail (URL: http://www.promedmail.org) and unpublished cases
from the personal archive of the authors were included if they met
the inclusion criteria.
The patients were allocated to the following groups:
1. Travelers: Patients with non-endemic background, namely
travelers, expatriates, and long-time residents who became
infected in Africa and treated in their country of origin
2. Immigrants: Migrated native Africans who were diagnosed and
treated in non-endemic regions
African HAT patients diagnosed and treated in endemic regions
were used for comparison. The species determination was based
on geographical localization. We collected all available data on
epidemiological background, clinical manifestations, laboratory
parameters, applied diagnostic methods, and treatment regimens
of the included cases. After extracting the data from the
publications fulfilling the inclusion criteria, the clinical and
laboratory characteristics as well as the neurological symptoms
between the 3 groups (T.b. rhodesiense infected travelers, T.b.
gambiense infected travelers and HAT infected immigrants) were
compared using the Fisher exact test (for binary variables) and the
Kruskal Wallis test (for continuous variables). A p-value,0.05 was
considered statistically significant. The statistical analyses were
performed using STATA 10.1 (Stata Corp LP, College Station,
TX, USA).
Results
One hundred twenty-one cases met the inclusion criteria: 99
cases from the literature search, 19 cases reported on ProMED-
mail, and three cases from the personal archives of the authors.
The references of all cases are listed in text S1.
The epidemiological data are summarized in Figures 1 and 2.
The description of the groups, the data on clinical findings,
laboratory results, diagnostic methods and response to treatment
are shown in Tables 1, 2, 3, 4, 5, 6.
Forty-five reports on travelers infected with T.b. rhodesiense and 15
reports on travelers infected with T.b. gambiense were included in the
analysis of the clinical parameters. Both species presented with fever
(T.b. rhodesiense 98%; T.b. gambiense 93%), headache (close to 50%
each), and a trypanosomal chancre (T.b. rhodesiense 84%; T.b.
gambiense 47%). While insomnia and diurnal somnolence dominate
the clinical presentation of HAT in endemic regions, insomnia (T.b.
rhodesiense 7%, T.b. gambiense 21%) or diurnal somnolence (T.b.
rhodesiense 5%, T.b. gambiense none) have only rarely been described
in travelers. Surprisingly, jaundice has been reported in 24% of T.b.
rhodesiense infected travelers. The analysis of 14 reports on HAT
infected immigrants (all infected with T.b. gambiense) shows that
neurological symptoms such as somnolence (46%), motor deficit
(64%) and reflex anomalies (14.3%) as well as psychiatric symptoms
such as hallucinations (21%) or depression (21%) may dominate the
clinical picture. Often, the diagnosis has been missed initially: some
patients have even been hospitalized in psychiatric clinics.
While 83% (34/41) of T.b. rhodesiense infected travelers had a
history of staying ,30 days and 17% (7/41).30 days within
endemic regions, 29% (4/14) of T.b. gambiense infected travelers
had spent ,30 days and 71% (10/14).30 days within endemic
regions.
The activities determining the risk of exposure in travelers
infected with T.b. rhodesiense included: visits to game parks 44/57
(77.2%), hunting safaris 5/57 (8.8%), military missions 4/57
(5.2%), business trips 2/57 (3.5%), and being expatriate 2/57
(3.5%). The main activities determining the risk of exposure in
travelers infected with T.b. gambiense were: traveling as tourists 3/
16 (18.8%), business trips 5/16 (31.3%) and being expatriate 8/16
(50%).
The putative incubation period was estimated to be #14 days in
39/54 (72%) and 15 to 21 days in 11/54 (20%) travelers infected
with T.b. rhodesiense. In 4/54 (7%) patients, the time of infection
was not precisely known, but - considering the maximal range of
exposure - less than 30 days. The incubation period in travelers
infected with T.b. gambiense has been ,21 days in 4/7 (57%), 21 to
30 days in 1/7 (14%) and .3 months in 2/7 (29%) patients. The
incubation period in immigrants was estimated - considering the
time of leaving the endemic region and the appearance of the first
symptom - to be ,5 months in 3/10 (30%), .two years in 6/10
(60%) and even .7 years in 1/10 (10%) patients.
ECG findings have not been routinely described among the
reviewed cases. In 14 travelers the following abnormalities have
been reported: in the T.b. rhodesiense group 4/10 (40%) have been
normal, 1/10 (10%) has shown sinustachycardia, 4/10 (40%) ST-
and T- wave abnormalities, and 1/10 (10%) a first degree
atrioventricular block. In the T.b. gambiense group, 1/4 (25%) has
been normal, 2/4 (50%) have presented a first degree atrioven-
tricular block, and 1/4 (25%) a third degree atrioventricular block.
One single investigation of peripheral blood smears has
established the diagnosis in 57/64 (89%) T.b. rhodesiense infected
Author Summary
We systematically reviewed the existing literature, col-
lected 95 cases of Human African Sleeping Sickness in
travelers and expatriates from non-endemic countries, and
observed that Sleeping Sickness in travelers generally
presents as an acute febrile illness irrespective of the
causative species. If present, a trypanosomal chancre or
rash and itching are important diagnostic clues. Diarrhea,
hepatomegaly, or jaundice are frequent and may lead to a
wrong gastroenterological diagnosis. Contrary to endemic
populations, where lymphadenopathy (‘Winterbottom
sign’) or sleep disorders are hallmarks of the disease, such
alterations are only occasionally found in patients from
non-endemic regions. The progression of the disease to
the second stage is rapid and it is only treatable with toxic
drugs. The risk of a fatal outcome exists and requires a
rapid diagnosis and start of treatment. The clinical
presentation in immigrants with human African Trypano-
somiasis (HAT) is dominated by low grade fever and
neurological symptoms as well as psychiatric features.
Because of the long incubation period, HAT must be
considered even if the patient has left the endemic
country years ago.
Sleeping Sickness in Travelers
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Repeated examinations have been necessary in eleven patients. In
four immigrants, trypanosomes could not be detected by
microscopical analysis of peripheral blood or CSF. In one patient,
the diagnosis has been established by positive serology and
detection of ‘‘Mott’’ cells in bone marrow aspirates; in a second
patient by finding ‘‘Mott’’ cells in a brain biopsy; in a third patient
by positive serology and histological findings consistent with T.b.
gambiense infection; and in a fourth patient by using a PCR assay of
the buffy coat and CSF samples.
Travelers infected with T.b. rhodesiense in the first stage have been
treated with suramin (42/53 patients (79,2%)). Because suramin
was not available, the following alternatives have been used to
treat 11 patients: pentamidine (5/53 patients (9.4%)), pentamidine
followed by suramin (5/53 patients (9.4%)), and melarsoprol (1/53
patient (1.9%)). All 17 second stage T.b. rhodesiense patients have
been treated with melarsoprol. Out of all T.b. rhodesiense infected
travelers, three patients died and three had relapses. Two have
died of an encephalopathic syndrome due to melarsoprol and one
due to severe complications (disseminated intravascular coagula-
tion, cardiac arrhythmia, pneumonia, and generalized seizure).
Among the T.b. gambiense infected travelers, no patient has died.
T.b. gambiense infected patients (both travelers and immigrants)
with first stage HAT have been treated with pentamidine (10/14
patients (71.4%)), suramin (2/14 patients (14.3%)) and eflornithin
(2/14 patients (14.3%)). The patients in second stage HAT have
been treated with eflornithine (17/29 patients (58.6%)) or
melarsoprol (12/29 patients (41.4%)).
Discussion
In contrast to African patients in whom the clinical presentation
of chronic T.b. gambiense and acute T.b. rhodesiense infections are
distinctly different, both species present as acute febrile illness in
travelers with few differences. Sleeping disorders and neurological
findings do not dominate the clinical presentation.
Fever
Patients infected with both species have presented with fever
$37.5uC( T.b. rhodesiense 98%; T.b. gambiense 93%). The fever has
Figure 1. HAT in endemic and non-endemic populations (traveler). In 14 patients, more than one country was estimated to be country of
infection: Kenya or Tanzania: 7; Cameroon or Congo: 2; Nigeria or Gabon: 1; Zambia or Botswana: 1, Zambia, Zimbabwe or Tanzania: 1; Namibia,
Mozambique or Malawi: 1, East Africa: 1 (these patients are not counted in the figure). The black line divides the endemic regions of T.b. gambiense
and T.b. rhodesiense HAT. Modified data from Simarro P. et al. 2011.
doi:10.1371/journal.pntd.0001358.g001
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species: T.b. rhodesiense (67%), T.b. gambiense (53%). In endemic
patients high fever has less frequently been reported in T.b.
gambiense [2–5] than in T.b. rhodesiense HAT [6–8]. Possible
explanations for this difference may be due to genetic factors or
a lack of previous exposure to non-human-pathogenic forms of
trypanosomes, possibly contributing to the development of partial
immunity. Sporadic cases of such human infections with putative
non-human-pathogenic trypanosomes have been reported [9–11].
Sleeping disorders and other neurological disorders
A key finding of this review is that the classical sleep disorders of
HAT and neurological findings are not a hallmark in travelers,
irrespective of species. Sleep disorders have only been present in a
minority of T.b. rhodesiense infected travelers. Nighttime insomnia
has only been observed in 21% of T.b. gambiense infected travelers.
Apart from tremor and motor deficits in 15% of T.b. gambiense
infected patients neurological and psychiatric findings have not
been reported in travelers. In general, the eponymous sleep
disorders of second stage HAT are mostly seen in patients infected
with T.b. gambiense (see Table 7) [2]. This is commonly explained
by the prolonged course of second stage disease [2]. Further, the
incidence of neurological disorders increases with the evolution of
the disease in both species [2,3]. Since most of the travelers have
been in the first stage and had a short duration of the disease, sleep
disorders and neuropsychiatric findings may not have been
developed at the time of the first clinical assessment. In addition,
nighttime insomnia may have been overlooked and underreported
because of its relatively benign character in an otherwise acute and
often life threatening disease. Somnolence is a common and
unspecific symptom in any severe febrile disease and might
therefore be underreported. The absence or presence of sleep
disorders or other neuropsychiatric findings in travelers may not
be decisive for the assessment of HAT. In contrast, somnolence
and the classical disruption of the sleep cycle with daytime
somnolence and nighttime insomnia, as well as other neuropsy-
chiatric findings, are frequently observed in immigrants.
Chancre and other skin alterations
While in endemic populations a trypanosomal chancre is rarely
seen [4,5], a trypanosomal chancre is a key finding in 84% of T.b.
rhodesiense and 47% of T.b. gambiense infected travelers (see table 7).
The presence of a trypanosomal rash might be an important
diagnostic clue; this exanthema, which may appear at any time
after the first febrile episode, consists of blotchy irregular
erythematous macules with a diameter of up to 10 cm. A large
proportion of the macules develop a central area of normal-
colored skin, giving the rash a circinate or serpiginous outline. The
trunk is mainly affected and the erythema is seldom pronounced.
The rash is evanescent, fading in one place and reappearing in
another over a period of several weeks. It is not tender and does
not itch [6,7]. In our study, such a trypanosomal rash has been
present in approximately one third of the travelers, irrespective of
the species.
Pruritus is a well known symptom of Western [2,8,12,13] and –
to a lesser extent [14–16] - Eastern HAT. Among our reviewed
cases, pruritus has been present in 20% of the travelers infected
with T.b. gambiense, but only in 4% of the travelers infected with
T.b. rhodesiense. In the differential diagnosis of fever in returning
travelers pruritus and the respective scratch marks might constitute
valuable diagnostic clues for T.b. gambiense HAT.
Gastrointestinal findings
Liver involvement with clinical hepatomegaly and elevated liver
function tests (LFT) is a known feature of HAT [2,3,5,8,15–18].
Figure 2. Sleeping sickness reported cases over the years in travelers. Note: The date refers to the date of diagnosis, not to the publication
date of the case.
doi:10.1371/journal.pntd.0001358.g002
Table 1. Description of the groups.
Number Travelers Immigrants
T.b.
rhodesiense
T.b.
gambiense
T.b.
gambiense
Total 121 74 21 26
Male/female 76/36 43/22 19/2 14/12
Age (mean) 39.4 42.3 39.0 32.4
Stage 1/Stage 2 67/47 53/17 14/7 0/23
doi:10.1371/journal.pntd.0001358.t001
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Travelers Immigrants Fisher test p-value
T.b. rhodesiense T.b. gambiense T.b. gambiense
n=45 n=15 n=11
%%%
Moderate fever (37.5–38.5uC) 31.1 40.0 54.6 0.336
High fever (.38.5uC) 66.7 53.3 36.4 0.150
Chills 28.9 20 0 0.108
Trypanosomal chancre 84.4* 46.7* 9.1 0.0001
*0.0034
Trypanosomal rash 28.9 33.3 0 0.79
Headache 48.9 53.3 36.4 0.698
Pruritus 4.4 20.0 9.1 0.102
Weight loss 8.9* 40.0* 18.2 0.020
*0.005
Diarrhea 17.8 6.7 0 0.342
Nausea /vomiting 37.8 20 0 0.029
Myalgia 22.2 20 27.3 0.921
Jaundice 24.2* 0* 0 0.028
*0.034
Lymphadenopathy generalized 13.3* 40.0* 66.7 0.001
*0.025
Lymphadenopathy satellite to chancre 26.7 33.3 8.3 0.316
Splenomegaly 27.3* 60.0* 27.3 0.067
*0.022
Hepatomegaly 17.8 33.3 27.3 0.388
Tachycardia (.100/min) 11/20=55 5/8=62.5 No data 0.510
Hypotension (systolic,100) 3/14=21.4 1/5=20 No data 1.000
A * behind a number signifies a significant difference between T.b. gambiense and T.b. rhodesiense travelers.
doi:10.1371/journal.pntd.0001358.t002
Table 3. Neurological and psychiatric symptoms.
Travelers Immigrants Fisher test p-value
T.b. rhodesiense T.b. gambiense T.b. gambiense
n=42 n=14 n=14
%% %
Personality change 0 0 14.3 0.075
Hallucinations 4.8 0 21.4 0.102
Depression 0 0 21.4 0.013
Tremor 4.9 14.3 21.4 0.131
Abnormal reflexes 0 7.7 23.1 0.012
Reduced level of consciousness 2.5 0 42.9 0.0001
Extrapyramidal symptoms 2.5 0 14.3 0.202
Sensory deficit 0 7.7 14.3 0.064
Motor deficit 0* 15.4* 64.3 0.001
*0.0115
Daytime somnolence 4.8 0 46.2 0.001
Nighttime insomnia 7.1 21.4 0 0.168
Daytime somnolence & nighttime insomnia 2.6 7.1 23.1 0.034
doi:10.1371/journal.pntd.0001358.t003
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immigrants and travelers. Interestingly 24% of the travelers
infected with T.b. rhodesiense have been with jaundice, a sign that
has only occasionally been reported in HAT infected immigrants
[2,3,5,8,15–19] (table 2). Our review highlights the fact that T.b.
rhodesiense HAT should be included in the differential diagnoses of
febrile travelers presenting with jaundice or abnormal LFT.
Further clinical findings
No textbook on the clinical description of the Human African
Sleeping Sickness will omit the classical description of the
‘‘Winterbottom’s sign’’, the cervical lymphadenopathy, which is
mostly described as a characteristic trait of HAT. Among the
reviewed HAT cases, general lymphadenopathy has been reported
in a majority of T.b. gambiense infected immigrants (Table 2). In
travelers, however, lymphadenopathy is absent in the majority of
cases and does therefore not facilitate diagnosis.
Cardiac involvement with myopericarditis, arrythmias and ECG
changes (QTc prolongation, repolarisation changes, and low
voltage) has been observed in endemic HAT patients [20]. While
clinically relevant heart failure is rarely observed in T.b. gambiense
HAT [21,22], myopericarditis appears to play an important role in
the clinical course and fatal outcome of T.b. rhodesiense infected
endemic population [22]. The few data on cardiac involvement in
travelers include myopericarditis [23,24], transient second degree
[25] and third degree atrioventricular block [26], and ventricular
premature captures (class Lown IV b) [26].
The kidney function has been impaired in most T.b. rhodesiense
travelers (83%). In contrast to endemic populations, where
endocrine disorders of the thyroid and adrenocortical function
[17,27,28] are described, no such alterations have been reported
in travelers. The white blood cell count has been mostly normal or
even low, and most patients presented thrombocytopenia.
Epidemiology
Numbers of HAT cases have markedly decreased in endemic
countries in the past decade – after an increase between 1969 and
2000 [29] –, while the number of reported HAT cases in non-
endemic countries shows a considerable increase (Figure 2). When
interpreting these epidemiological developments, it is important to
Table 4. Laboratory parameters.
Travelers Immigrants Fisher test p-value
T.b. rhodesiense T.b. gambiense T.b. gambiense
Elevated inflammatory parameter
1 8/8=100% 8/9=88.9% 6/6=100% 1.000
WBC,3.54610
3/mm
3 15/43=34.9% 3/7=42.9% 1/12=8.3% 0.164
WBC.9.06610
3/mm
3 5/43=11.6% 2/7=28.6% 3/12=25% 0.289
Hb,12 g/dl (female) & ,13.3 g/dl (male) 18/34=52.9% 8/9=88.9% 11/11=100% 0.003
*0.0489
Platelets,165 000/mm
3 37/42=88.1% 3/5=60% 5/8=62.5% 0.082
Elevated liver enzymes
# 31/35 s=80.7% 1/3=33.3% 0/3=0% 0.005
Total bilirubin.1.3 mg/dl 17/22=77.3% No data 0/2=0% 0.076
Creatinin.0.9 mg/dl (female) & .1.2 (male) 24/29=82.8% 0/3=0% 0/4=0% 0.0016
*0.001
Normal reference of value out of Harrison’s Online (http://www.accessmedicine.com/popup.aspx?aID=2904606, date: 10.11.2010).
1At least one of the following parameters was elevated: C-reactive protein (CRP).3.0 mg/L; erythrocyte sedimentation rate female.20 mm/h, male.15 mm/h.
#At least one of the following parameters was elevated: Alanin aminotransferase (SGOT, ALAT).7–41 U/l; Aspartate aminotransferase (SGPT, ASAT).12–38 U/l; Alkaline
Phosphatase (ALP).60–170 U7l).
doi:10.1371/journal.pntd.0001358.t004
Table 5. Diagnostic methods.
Number Travelers Immigrants
T.b. rhodesiense T.b. gambiense T.b. gambiense
(n=121) (n=74) (n=21) (n=26)
Blood smear 76 64 9 3
Buffy coat test 1 0 1 0
PCR of the buffy coat 1 0 0 1
Chancre fluid aspirate 2 2 0 0
Lymph node aspirate 1 0 1 0
Bone marrow aspirate 1 0 1 0
CSF microscopy 12 0 2 10
Serology and cytology /histology (mott cells) 3 0 0 3
No data 24 8 7 9
doi:10.1371/journal.pntd.0001358.t005
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rhodesiense HAT. In endemic regions T.b. gambiense is responsible for
more than 95% of all HAT patients [30]; in travelers only a
minority of HAT (22%) are due to T.b. gambiense. Humans are
considered to be the main reservoir of T.b. gambiense [31] and
animals (e.g. pigs, dogs, etc.) play a minor role [31]. The decline of
T.b. gambiense HAT was mainly achieved by ambitious campaigns
enforcing large scale screening and treatment programs in endemic
regions, targeting the human main reservoir [29]. In contrast, T.b.
rhodesienseis primarilya zoonotic disease with wild gameanimals and
cattle as main reservoir [31]. The increasing number of HAT
observed in travelers over the last decades may be explained by the
growing number of tourists who visit T.b. rhodesiense endemic game
parks in Eastern Africa on safari and hunting trips and – to a lesser
extent – by the re-emergence of HAT in the Serengeti National
Park (Tanzania) in the years 2000–2005 [32].
Incubation period
The incubation period of T.b. gambiense in endemic regions is
difficult to assess, as the time of infection is unknown. Therefore,
Table 6. Response to treatment.
Number Travelers Immigrants
T.b. rhodesiense T.b. gambiense T.b. gambiense
(n=121) (n=74) (n=21) (n=26)
Cure 95 58 19 18
Death 5 3 0 2
Relapse 7 3 2 2
No data 14 10 0 4
doi:10.1371/journal.pntd.0001358.t006
Table 7. Signs and symptoms according to stage and affected population.
Population T.b. gambiense T.b. rhodesiense
First stage Second stage First stage Second stage
Incubation period Natives 18 months [34] 18 months [34] 1–3 weeks few weeks
Travelers 75% ,1 month No data ,3 weeks .4 weeks
Chancre Natives ,5% [12,13,35] 0 [8,11] 5–26% [3,5,14,15,36] 0 [3,16]
Travelers 55.6% 33% 87.9% 75%
Trypanosomal rash Natives 0% [12,13,35] 0 [8,11] 0% [5,14,36] 0 [3,16]
Travelers 22.2% 50% 24.4% 41.7%
Fever ($37.56C) Natives 10–20% [12,13,35] 10–40% [8,11–13,19,35,37,38] 28–90% [3,5] 18–37% [3,15,16,36]
272% [14]
Travelers 88.9%; .38.5u: 55.6% 100%; .38.5u: 50% 100%; .38.5u: 72.7% 91.7%; .38.5u:5 0 %
Lymphadenopathy Natives 79–95% [12,13,35] 56–85% [8,11–13,35] 21% [3] 51–80% [3,14–16,36]
Travelers Generalized 33.3%
Satellite (to chancre) 22.2%
Generalized 50%
Satellite (to chancre) 50%
Generalized 6.1%
Satellite (to chancre) 30.3%
Generalized 33.3%
Satellite (to chancre) 16.7%
Sleeping disorder Natives Somnolence 18%
Insomnia 73% [13]
Somnolence 29–41% [8,11]
Insomnia 25–57% [8,11,13]
Somnolence 25–33% [3,5] Somnolence 54–66%
Insomnia 28–64%
[3,14–16,36]
Travelers Somnolence 0%
Insomnia 28.6%
Somnolence 0%
Insomnia 16.7%
Somnolence 0%
Insomnia 6.7%
Somnolence 16.7%
Insomnia 8.3%
Pruritus Natives 29–33% [12,13,39] 17–57% [8,11–13,39] 0% [3] 6–53% [14–16]
Travelers 22.2% 16.7% 3% 8.3%
Headache Natives 51–80% [12,39] 38–79% [8,11–13,39,40] 96% [5] 51–80% [3,16]
Travelers 55.5% 50% 42.4% 66.7%
Hepatomegaly Natives 0–20% [12,13,39] 7–17% [8,13] 0–40% [3] 6–30% [3,16]
Travelers 22.2% 50% 15.6% 25%
Splenomegaly Natives 9–27% [12,13,39] 5–19% [8,12,13] 0–36% [3] 16–58% [3,16]
Travelers 55.6% 66.7% 30.3% 8.3%
Tremor Natives 5% [35] 19–21% [8,41] 17–61% [3] 16–67% [3,16]
Travelers 14.3% 0% 0% 16.7%
Neurological disorder Natives ,20% [12,13] 20–40% [11,13] ,20% [3] 50–58% [3,16]
Travelers 25% 33.3% 0% 8.3%
Psychiatric disorders Natives ,10% 25% [11] 17% [36] 15–22% [3,16]
Travelers 0% 0% 3.3% 8.3%
Kidney impairment Natives rare [42] rare [17,42] unknown [3] unknown
Travelers 0% 0% 85% 77.7%
doi:10.1371/journal.pntd.0001358.t007
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have left endemic countries. Since one immigrant patient
developed HAT seven years after migration to a non-endemic
area, the incubation period may be seven years or even longer.
T.b. gambiense HAT should be considered in any patient from an
endemic region who presents with diffuse neurological symptoms,
even if already having lived abroad for a prolonged period of time.
The incubation period has been ,14 days in 72% of the T.b.
rhodesiense infected travelers, and ,one month in all of them. In
contrast, the incubation period in 28% of T.b. gambiense infected
travelers has been longer, even exceeding three months.
Diagnosis
Travelers have mostly been diagnosed by finding trypanosomes
in thin or thick blood smears. Mostly, the laboratory diagnosis has
easily been established in T.b. rhodesiense patients, usually due to
suspicionfrom clinical findings. However, in T.b. gambiense infected
patients repeated blood examinations and concentration methods
have often been necessary [33]. Microscopic analysis of chancre
fluid aspiration has allowed an early diagnosis in two patients. In
immigrants the diagnosis has been especially difficult. Parasites
have rarely been present in blood smears and analyzes of the CSF.
Serologic testing or further diagnostics have been necessary.
Treatments
The treatment of travelers follows the treatment guidelines for
sleeping sickness in the endemic regions. The number of our
reviewed HAT cases in travelers is too small to conclude on the
toxicity or cure rates of the different drugs and treatment
regimens. However, it is remarkable that five out of 17 (29.4%)
patients with second stage T.b. rhodesiense HAT have developed an
encephalopathic syndrome during treatment with melarsoprol and
two of them have died. A publication bias or a delayed diagnosis
and treatment could be an explanation. In some of the reviews
from first stage T.b. rhodesiense HAT cases, suramin has initially not
been available. In these cases, the treatment has been initiated
using the more easily available drug pentamidine, switching to
suramin later. This approach has shown good clinical response.
Study limitations
Limitations of this study are due to the incomplete epidemio-
logical, clinical, and laboratory data due to the retrospective
nature of this study. A publication bias cannot be ruled out;
however, since clinicians are impressed by this rare disease, it is
likely that many cases are published, as demonstrated by the long
list of references. Our search may have missed publications of
travelers that had not ‘‘travel’’ or ‘‘traveler’’ as key words. First
and second stage patients were not described separately because of
the small number of second stage patients. Our aim was to
describe the typical clinical features of HAT in travelers that might
confront the physician on an initial medical consultation.
Conclusions and recommendations
With rising number of tourists traveling to HAT endemic
regions, Sleeping Sickness must be included in the differential
diagnosis of any febrile patient, especially in the presence of
suspicious skin manifestations or gastrointestinal manifestations.
In contrast to HAT patients in endemic regions, Sleeping
Sickness in travelers generally presents as an acute febrile illness,
irrespective of the causative species (see Table 7). If present, a
trypanosomal chancre or rash and itching are important
diagnostic clues. Diarrhea, hepatomegaly, or icterus are frequent
and may lead to a wrong gastroenterologic diagnosis. In contrary
to endemic populations, where lymphadenopathy (Winterbottom
sign) or sleep disorders are hallmarks of the disease, such
alterations are only occasionally found in travelers. The rapid
progression of the disease to the second stage - in which it is only
treatable with toxic drugs and the risk of a fatal outcome exists -
requires a rapid diagnosis and start of treatment. The clinical
presentation of HAT in immigrants is similar to the presentation of
HAT patients in endemic regions (see Table 7) and is dominated
by low grade fever as well as neurological and psychiatric features.
Because of the long incubation period, HAT has to be considered
even if the patient has left endemic regions years ago.
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